Literature DB >> 18055943

Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis.

P French1, N Shryane, R P Bentall, S W Lewis, A P Morrison.   

Abstract

BACKGROUND: There have been recent advances in the identification of people at high risk of psychosis and psychological treatments have shown promise for prevention. AIMS: To compare the longitudinal course of psychotic experiences and emotional dysfunction in high-risk participants receiving cognitive therapy with those receiving treatment as usual.
METHOD: Data from a recent randomised controlled trial of cognitive therapy for people at risk of developing psychosis were utilised to examine three different statistical models that were based on 432 measurements of psychotic experiences and 421 of emotional dysfunction (anxiety-depression) contributed by 57 participants across the 13 measurement occasions (monthly monitoring for a year).
RESULTS: Psychotic experiences and emotional dysfunction were correlated and decreased significantly over the course of the study, with most improvement in the early months. The reduction in positive symptoms, but not emotional dysfunction, was enhanced by allocation to cognitive therapy.
CONCLUSIONS: Psychotic experiences and emotional dysfunction appear to interact in people at risk of developing psychosis. There appears to be a specific benefit of cognitive therapy.

Entities:  

Mesh:

Year:  2007        PMID: 18055943     DOI: 10.1192/bjp.191.51.s82

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  8 in total

1.  Dynamic association between interpersonal functioning and positive symptom dimensions of psychosis over time: a longitudinal study of healthy adolescents.

Authors:  Dina Collip; Johanna T W Wigman; Ashleigh Lin; Barnaby Nelson; Margreet Oorschot; Wilma A M Vollebergh; Jaymee Ryan; Gennedy Baksheev; Marieke Wichers; Jim van Os; Inez Myin-Germeys; Alison R Yung
Journal:  Schizophr Bull       Date:  2011-09-19       Impact factor: 9.306

Review 2.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 3.  Cognitive behavioral therapy in prodromal psychosis.

Authors:  Jean Addington; Catherine Marshall; Paul French
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Evaluation and treatment of children and adolescents with psychotic symptoms.

Authors:  Sibel Algon; James Yi; Monica E Calkins; Christian Kohler; Karin E Borgmann-Winter
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

5.  Use of Palm computer as an adjunct to cognitive-behavioural therapy with an ultra-high-risk patient: a case report.

Authors:  David Kimhy; Cheryl Corcoran
Journal:  Early Interv Psychiatry       Date:  2008-11       Impact factor: 2.732

6.  The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample.

Authors:  Elaine F Walker; Barbara A Cornblatt; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Scott W Woods; Robert Heinssen
Journal:  Schizophr Res       Date:  2009-08-25       Impact factor: 4.939

7.  Interventions for prodromal stage of psychosis.

Authors:  Dina Bosnjak Kuharic; Ivana Kekin; Joanne Hew; Martina Rojnic Kuzman; Livia Puljak
Journal:  Cochrane Database Syst Rev       Date:  2019-11-01

8.  Psychological interventions for people with psychotic experiences: protocol for a systematic review and meta-analysis.

Authors:  Emma Soneson; Debra Russo; Clare Knight; Louise Lafortune; Margaret Heslin; Jan Stochl; Alex Georgiadis; Julieta Galante; Robbie Duschinsky; Nick Grey; Leticia Gonzalez-Blanco; Juliet Couche; Michelle Griffiths; Hannah Murray; Nesta Reeve; Joanne Hodgekins; Paul French; David Fowler; Sarah Byford; Mary Dixon-Woods; Peter B Jones; Jesus Perez
Journal:  Syst Rev       Date:  2019-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.